Global burden of moyamoya syndrome in pediatric sickle cell disease and implications for the neurosurgical workforce: a systematic review.
Joseline Haizel-Cobbina, Anne Heukwa-Tefoung, Soumya Pahari et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review quantified the global burden of moyamoya syndrome (MMS) in pediatric sickle cell disease (pSCD) and estimated the need for surgical evaluation. Among 2045 pSCD patients, 1.5% were diagnosed with pSCD|MMS, with 49.8% of these patients undergoing surgical revascularization. The projected global cases of pSCD|MMS are 36,587, with 18,219 potentially benefiting from surgery.
Key findings
- 1.5% of pediatric sickle cell disease patients were diagnosed with moyamoya syndrome.
- 49.8% of patients with moyamoya syndrome underwent surgical revascularization.
- The projected number of moyamoya syndrome cases worldwide is 36,587.
- The African region has the highest burden, with 32,189 projected cases.
Why it matters
Understanding the burden of moyamoya syndrome in pediatric sickle cell disease is crucial for healthcare planning. It highlights the need for improved diagnostic and surgical resources, particularly in regions with limited infrastructure, to enhance patient outcomes.
What to keep in mind
Projections are based on a limited number of studies with geographic variability, which may affect the accuracy of the estimates.